TABLE 2.
Comparison of demographic and clinicopathologic characteristics between time intervals for clinical stage I and clinical stage II
| 0-6 wk | 7-12 wk | P value | |
|---|---|---|---|
| Clinical stage I | n = 11 846 | n = 1041 | |
| Age at diagnosis (mean) | 67 ± 10 | 70 ± 10 | <.001 |
| Sex | |||
| Male | 5787 (50) | 496 (48) | .46 |
| Female | 5958 (50) | 545 (52) | |
| Race | |||
| White | 10 211 (86) | 870 (84) | <.001 |
| Black | 1088 (9) | 139 (13) | |
| Other | 547 (5) | 32 (3) | |
| Insurance status | |||
| Not insured | 213 (2) | 17 (2) | <.001 |
| Government insurance | 7285 (62) | 730 (71) | |
| Private insurance | 4254 (36) | 285 (28) | |
| Educational attainmenta | |||
| ≥17.6% | 2023 (17) | 183 (18) | <.001 |
| 10.9%-17.5% | 2950 (25) | 307 (30) | |
| 6.3%-10.8% | 3332 (28) | 312 (30) | |
| <6.3% | 3398 (29) | 227 (22) | |
| Facility location | |||
| Northeast | 2497 (21) | 235 (23) | .21 |
| South | 4216 (36) | 358 (35) | |
| Midwest | 3452 (29) | 285 (27) | |
| West | 1601 (14) | 159 (15) | |
| Charlson-Deyo score | |||
| 0 | 7517 (64) | 572 (55) | <.001 |
| 1 | 3277 (28) | 332 (32) | |
| ≥2 | 1052 (9) | 137 (13) | |
| Tumor differentiation | |||
| Well | 1195 (11) | 107 (12) | .49 |
| Moderate | 5811 (54) | 500 (55) | |
| Poor/undifferentiated | 3739 (35) | 298 (33) | |
| Tumor size, cm | |||
| <1 | 283 (2) | 32 (3) | .54 |
| 1-2 | 1455 (12) | 127 (12) | |
| 2-4 | 6862 (59) | 602 (59) | |
| >4 | 3092 (26) | 262 (26) | |
| AJCC pathologic stage (sixth or seventh edition) | |||
| Stage I | 2972 (25) | 266 (26) | .36 |
| Stage II | 8618 (73) | 747 (72) | |
| Stage III | 167 (1) | 15 (1) | |
| Treatment approach | |||
| Upfront surgery | 10 768 (91) | 882 (85) | <.001 |
| Neoadjuvant chemotherapy | 817 (7) | 106 (10) | |
| Neoadjuvant chemoradiation | 254 (2) | 53 (5) | |
| Surgery type | |||
| Local excision | 25 (0.2) | 0(0) | .14 |
| Partial pancreatectomy | 2149 (18) | 210 (20) | |
| Pacreatoduodenectomy | 7383 (62) | 655 (63) | |
| Total pancreatectomy | 1483 (13) | 118 (11) | |
| Extended pancreatoduodenectomy | 612 (5) | 41 (4) | |
| Not otherwise specified | 194 (2) | 17 (2) | |
| Surgical approach | |||
| Open | 6135 (84) | 562 (84) | .75 |
| Minimally invasive | 1187 (16) | 105 (16) | |
| Margin status | |||
| R0 | 9481 (81) | 826 (80) | .66 |
| R1 | 1415 (12) | 132 (13) | |
| R2 | 69 (1) | 6(1) | |
| Indeterminate | 756 (6) | 63 (6) | |
| Clinical stage II | n = 14 464 | n = 1209 | |
| Age at diagnosis (mean) | 66 ± 10 | 68 ± 10 | <.001 |
| Sex | |||
| Male | 7522 (52) | 643 (53) | .43 |
| Female | 6942 (48) | 566 (47) | |
| Race | |||
| White | 12 538 (87) | 1033 (85) | .157 |
| Black | 1322 (9) | 130 (11) | |
| Other | 604 (4) | 46 (4) | |
| Insurance status | |||
| Not insured | 341 (2) | 27 (2) | <.001 |
| Government insurance | 8261 (58) | 798 (67) | |
| Private insurance | 5666 (40) | 369 (31) | |
| Educational attainmenta | |||
| ≥17.6% | 2581 (18) | 224 (19) | .003 |
| 10.9%-17.5% | 3622 (25) | 334 (28) | |
| 6.3%-10.8% | 4150 (29) | 363 (30) | |
| <6.3% | 3957 (28) | 271 (23) | |
| Facility location | |||
| Northeast | 3193 (22) | 283 (24) | .635 |
| South | 5498 (38) | 449 (37) | |
| Midwest | 3760 (26) | 319 (27) | |
| West | |||
| Charlson-Deyo score | |||
| 0 | 9545 (66) | 748 (62) | .001 |
| 1 | 3833 (27) | 339 (28) | |
| ≥2 | 1086 (7) | 122 (10) | |
| Tumor differentiation | |||
| Well | 1069 (8) | 106 (10) | .04 |
| Moderate | 6864 (53) | 548 (53) | |
| Poor/undifferentiated | 5069 (39) | 376 (37) | |
| Tumor size, cm | |||
| <1 | 109 (1) | 10 (1) | .87 |
| 1-2 | 1069 (8) | 86 (7) | |
| 2-4 | 8149 (58) | 669 (57) | |
| >4 | 4797 (34) | 413 (35) | |
| AJCC pathologic stage (sixth or seventh edition) | |||
| Stage I | 628 (4) | 69 (6) | .17 |
| Stage II | 13 548 (94) | 1114 (92) | |
| Stage III | 244 (2) | 22 (2) | |
| Treatment approach | |||
| Upfront surgery | 11 860 (82) | 879 (73) | <.001 |
| Neoadjuvant chemotherapy | 2083 (14) | 228 (19) | |
| Neoadjuvant chemoradiation | 515 (4) | 99 (8) | |
| Surgery type | |||
| Local excision | 39 (0.3) | 4 (0.3) | .42 |
| Partial pancreatectomy | 1748 (12) | 169 (14) | |
| Pacreatoduodenectomy | 9484 (66) | 761 (63) | |
| Total pancreatectomy | 1911 (13) | 162 (13) | |
| Extended pancreatoduodenectomy | 950 (7) | 85 (7) | |
| Not otherwise specified | 332 (2) | 28 (2) | |
| Surgical approach | |||
| Open | 6937 (85) | 573 (86) | .58 |
| Minimally invasive | 1226 (15) | 95 (14) | |
| Margin status | |||
| R0 | 10 810 (76) | 915 (77) | .57 |
| R1 | 1978 (14) | 155 (13) | |
| R2 | 127 (1) | 6(1) | |
| Indeterminate | 1329 (9) | 106 (9) | |
Note: Percentages in parentheses exclude missing data. Bold indicates statistical significance at P < .05.
Abbreviation: AJCC, American Joint Committee on Cancer.
a
% in zip code without a high-school diploma.